Starpharma Holdings Limited (SPHRF)
USD 0.06
(7.53%)
USD 0.06
(7.53%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 | -8.16 Million AUD | 47.79% |
| 2023 | -15.63 Million AUD | 3.19% |
| 2022 | -16.15 Million AUD | 18.13% |
| 2021 | -19.73 Million AUD | -34.43% |
| 2020 | -14.67 Million AUD | -2.97% |
| 2019 | -14.25 Million AUD | -38.59% |
| 2018 | -10.28 Million AUD | -225.43% |
| 2017 | 8.2 Million AUD | 136.16% |
| 2016 | -22.67 Million AUD | -19.66% |
| 2015 | -18.95 Million AUD | -29.48% |
| 2014 | -14.63 Million AUD | -179.88% |
| 2013 | -5.22 Million AUD | 61.71% |
| 2012 | -13.65 Million AUD | -52.95% |
| 2011 | -8.93 Million AUD | -40.01% |
| 2010 | -6.37 Million AUD | -54.54% |
| 2009 | -4.12 Million AUD | 44.91% |
| 2008 | -7.49 Million AUD | -3.4% |
| 2007 | -7.24 Million AUD | 3.69% |
| 2006 | -7.52 Million AUD | 0.83% |
| 2005 | -7.58 Million AUD | -37.98% |
| 2004 | -5.49 Million AUD | -3040.52% |
| 2003 | -175.06 Thousand AUD | -429.32% |
| 2002 | 53.15 Thousand AUD | 101.36% |
| 2001 | -3.9 Million AUD | -120.43% |
| 2000 | -1.77 Million AUD | -51.56% |
| 1999 | -1.16 Million AUD | 8.0% |
| 1998 | -1.27 Million AUD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q3 | -3.56 Million AUD | -244.83% |
| 2024 Q1 | -517 Thousand AUD | 92.98% |
| 2024 Q2 | -1.03 Million AUD | -100.0% |
| 2024 FY | -8.16 Million AUD | 47.79% |
| 2024 Q4 | -3.56 Million AUD | 0.0% |
| 2023 Q3 | -3.68 Million AUD | 55.53% |
| 2023 Q4 | -7.36 Million AUD | -100.0% |
| 2023 Q1 | -4.13 Million AUD | 46.29% |
| 2023 Q2 | -8.27 Million AUD | -100.0% |
| 2023 FY | -15.63 Million AUD | 3.19% |
| 2022 Q3 | -3.85 Million AUD | 54.4% |
| 2022 Q4 | -7.7 Million AUD | -100.0% |
| 2022 FY | -16.15 Million AUD | 18.13% |
| 2022 Q1 | -4.22 Million AUD | 54.59% |
| 2022 Q2 | -8.44 Million AUD | -100.0% |
| 2021 Q3 | -4.65 Million AUD | 55.41% |
| 2021 Q1 | -5.21 Million AUD | 40.84% |
| 2021 Q2 | -10.43 Million AUD | -100.0% |
| 2021 FY | -19.73 Million AUD | -34.43% |
| 2021 Q4 | -9.3 Million AUD | -100.0% |
| 2020 Q3 | -4.4 Million AUD | 24.83% |
| 2020 Q1 | -2.93 Million AUD | 58.05% |
| 2020 Q4 | -8.81 Million AUD | -100.0% |
| 2020 Q2 | -5.86 Million AUD | -100.0% |
| 2020 FY | -14.67 Million AUD | -2.97% |
| 2019 Q1 | -3.63 Million AUD | -79.23% |
| 2019 Q4 | -6.98 Million AUD | -100.0% |
| 2019 FY | -14.25 Million AUD | -38.59% |
| 2019 Q3 | -3.49 Million AUD | 3.83% |
| 2019 Q2 | -3.63 Million AUD | 0.0% |
| 2018 Q1 | -3.11 Million AUD | 9.46% |
| 2018 Q4 | -2.02 Million AUD | 0.0% |
| 2018 FY | -10.28 Million AUD | -225.43% |
| 2018 Q3 | -2.02 Million AUD | 34.94% |
| 2018 Q2 | -3.11 Million AUD | 0.0% |
| 2017 Q3 | -3.44 Million AUD | 17.43% |
| 2017 Q2 | -4.16 Million AUD | 0.0% |
| 2017 Q1 | -4.16 Million AUD | 15.59% |
| 2017 FY | 8.2 Million AUD | 136.16% |
| 2017 Q4 | -3.44 Million AUD | 0.0% |
| 2016 Q4 | -4.93 Million AUD | 21.88% |
| 2016 Q3 | -6.32 Million AUD | -25.98% |
| 2016 Q2 | -5.01 Million AUD | 0.0% |
| 2016 Q1 | -5.01 Million AUD | 3.63% |
| 2016 FY | -22.67 Million AUD | -19.66% |
| 2015 FY | -18.95 Million AUD | -29.48% |
| 2015 Q4 | -5.2 Million AUD | 0.0% |
| 2015 Q3 | -5.2 Million AUD | -21.95% |
| 2015 Q2 | -4.26 Million AUD | 0.0% |
| 2015 Q1 | -4.26 Million AUD | 5.77% |
| 2014 Q2 | -2.78 Million AUD | 0.0% |
| 2014 FY | -14.63 Million AUD | -179.88% |
| 2014 Q4 | -4.53 Million AUD | 0.0% |
| 2014 Q3 | -4.53 Million AUD | -62.56% |
| 2014 Q1 | -2.78 Million AUD | -64.09% |
| 2013 Q3 | -1.69 Million AUD | -85.43% |
| 2013 Q4 | -1.69 Million AUD | 0.0% |
| 2013 FY | -5.22 Million AUD | 61.71% |
| 2013 Q1 | -916 Thousand AUD | 0.0% |
| 2013 Q2 | -916 Thousand AUD | 0.0% |
| 2012 FY | -13.65 Million AUD | -52.95% |
| 2011 FY | -8.93 Million AUD | -40.01% |
| 2010 FY | -6.37 Million AUD | -54.54% |
| 2009 FY | -4.12 Million AUD | 44.91% |
| 2008 FY | -7.49 Million AUD | -3.4% |
| 2007 FY | -7.24 Million AUD | 3.69% |
| 2006 FY | -7.52 Million AUD | 0.83% |
| 2005 FY | -7.58 Million AUD | -37.98% |
| 2004 FY | -5.49 Million AUD | -3040.52% |
| 2003 FY | -175.06 Thousand AUD | -429.32% |
| 2002 FY | 53.15 Thousand AUD | 101.36% |
| 2001 FY | -3.9 Million AUD | -120.43% |
| 2000 FY | -1.77 Million AUD | -51.56% |
| 1999 FY | -1.16 Million AUD | 8.0% |
| 1998 FY | -1.27 Million AUD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Nuo Therapeutics, Inc. | -3.17 Million USD | -157.454% |
| CNBX Pharmaceuticals Inc. | -3.71 Million USD | -120.067% |
| Mosaic ImmunoEngineering Inc. | -2.38 Million USD | -242.942% |
| Evofem Biosciences, Inc. | 52.97 Million USD | 115.412% |
| GB Sciences, Inc. | -1.36 Million USD | -499.628% |
| Inhibitor Therapeutics, Inc. | -3.02 Million USD | -169.816% |
| NanoSphere Health Sciences Inc. | -228.12 Thousand USD | -3479.147% |
| Skye Bioscience, Inc. | -37.64 Million USD | 78.31% |
| Zenith Capital Corp. | -10.59 Million USD | 22.943% |
| Agentix Corp. | -1.37 Million USD | -494.159% |
| Arch Therapeutics, Inc. | -6.98 Million USD | -16.93% |
| Biomind Labs Inc. | -1.21 Million USD | -572.393% |
| ContraFect Corporation | -65.15 Million USD | 87.468% |
| CSL Limited | 2.64 Billion USD | 100.309% |
| CytoDyn Inc. | -49.84 Million USD | 83.618% |
| GlobeStar Therapeutics Corporation | -1.94 Million USD | -318.879% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -1191.099% |
| Northwest Biotherapeutics, Inc. | -62.59 Million USD | 86.957% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -1865.202% |
| Propanc Biopharma, Inc. | -1.82 Million USD | -348.496% |
| Regen BioPharma, Inc. | 1.02 Million USD | 897.747% |
| Santhera Pharmaceuticals Holding AG | 65.13 Million USD | 112.536% |
| SQZ Biotechnologies Company | -79.46 Million USD | 89.725% |
| Therapeutic Solutions International, Inc. | -2.16 Million USD | -276.3% |
| Eiger BioPharmaceuticals, Inc. | -74.96 Million USD | 89.108% |
| Intellipharmaceutics International Inc. | -2.89 Million USD | -182.292% |
| Mesoblast Limited | -87.95 Million USD | 90.717% |
| Marizyme, Inc. | -65.34 Million USD | 87.505% |
| Genus plc | 7.9 Million USD | 203.354% |
| Pharming Group N.V. | -10.54 Million USD | 22.592% |
| Nymox Pharmaceutical Corporation | -8.84 Million USD | 7.678% |
| RegeneRx Biopharmaceuticals, Inc. | -1.72 Million USD | -372.661% |
| IMV Inc. | -36.48 Million USD | 77.621% |
| AXIM Biotechnologies, Inc. | -8.05 Million USD | -1.307% |
| MultiCell Technologies, Inc. | -380.07 USD | -2148188.473% |
| ONE Bio Corp. | 8.67 Million USD | 194.104% |
| RVL Pharmaceuticals plc | -51.69 Million USD | 84.205% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| Emmaus Life Sciences, Inc. | -3.73 Million USD | -118.725% |
| Provectus Biopharmaceuticals, Inc. | -3.1 Million USD | -163.237% |
| Oncotelic Therapeutics, Inc. | -7.9 Million USD | -3.314% |
| THC Farmaceuticals, Inc. | -14.97 Thousand USD | -54420.566% |
| Acro Biomedical Co., Ltd. | -15.87 Million USD | 48.555% |
| Alpha Cognition Inc. | -13.77 Million USD | 40.715% |
| Enzolytics Inc. | -2.17 Million USD | -275.086% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -295.05 Million USD | 97.233% |
| Enzon Pharmaceuticals, Inc. | 98 Thousand USD | 8431.633% |
| Endonovo Therapeutics, Inc. | 6.92 Million USD | 217.913% |
| Genscript Biotech Corporation | -95.47 Million USD | 91.448% |
| Nanobac Pharmaceuticals, Incorporated | -6.57 Million USD | -24.162% |
| Institute of Biomedical Research Corp. | -273.4 Thousand USD | -2886.445% |
| Sigyn Therapeutics, Inc. | -4.14 Million USD | -96.94% |
| WPD Pharmaceuticals Inc. | -60.44 Thousand USD | -13409.129% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -307.209% |
| VioQuest Pharmaceuticals, Inc. | -10.89 Million USD | 25.035% |
| PsyBio Therapeutics Corp. | -4.88 Million USD | -67.108% |
| Adynxx, Inc. | - USD | Infinity% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| Accustem Sciences Inc. | -3.74 Million USD | -117.941% |
| Helix BioMedix, Inc. | -1.05 Million USD | -673.159% |
| EV Biologics, Inc. | -1.26 Million USD | -544.368% |
| Q BioMed Inc. | -2.05 Million USD | -297.886% |
| Capstone Therapeutics Corp. | -3.81 Million USD | -113.799% |
| American Oriental Bioengineering, Inc. | -59.72 Million USD | 86.329% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| BioStem Technologies, Inc. | -8.48 Million USD | 3.748% |
| Curative Biotechnology, Inc. | -5.81 Million USD | -40.358% |
| HST Global, Inc. | -146.21 Thousand USD | -5484.433% |
| Burzynski Research Institute, Inc. | -1.33 Million USD | -511.413% |
| Wesana Health Holdings Inc. | -1.75 Million USD | -365.303% |
| Halberd Corporation | -79.67 Thousand USD | -10147.753% |
| Resverlogix Corp. | -3.61 Million USD | -126.177% |
| Cell Source, Inc. | -5.32 Million USD | -53.442% |
| RespireRx Pharmaceuticals Inc. | -3.97 Million USD | -105.513% |
| GeneThera, Inc. | - USD | Infinity% |
| AVAX Technologies, Inc. | -6.41 Million USD | -27.307% |
| Ember Therapeutics, Inc. | -23.24 Thousand USD | -35030.367% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| NovAccess Global Inc. | -4.76 Million USD | -71.203% |
| Kadimastem Ltd | -3.3 Million USD | -146.871% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Rasna Therapeutics, Inc. | -4.44 Million USD | -83.791% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -441.36 Thousand USD | -1749.926% |
| LadRx Corporation | 400.44 Thousand USD | 2138.992% |
| Regen BioPharma, Inc. | 1.02 Million USD | 897.747% |
| Affymax, Inc. | -14.42 Million USD | 43.393% |
| Itoco Inc. | -1.86 Million USD | -336.866% |
| Pathfinder Cell Therapy, Inc. | -1.66 Million USD | -389.215% |
| Mobile Lads Corp. | -2.26 Million USD | -260.758% |
| International Stem Cell Corporation | -131 Thousand USD | -6132.824% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| Bioxytran, Inc. | -4.28 Million USD | -90.771% |
| NDT Pharmaceuticals Inc. | -79.03 Thousand USD | -10231.128% |
| Qrons Inc. | -789.34 Thousand USD | -934.399% |
| Alseres Pharmaceuticals, Inc. | -941.52 Thousand USD | -767.206% |
| SYBLEU INC | -180.3 Thousand USD | -4428.463% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | -2.08 Million USD | -291.104% |
| Rebus Holdings, Inc. | -1.02 Million USD | -700.49% |
| ImmunoCellular Therapeutics, Ltd. | -1.61 Million USD | -406.282% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -54.27 Thousand USD | -14944.59% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.53 Million USD | -222.696% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -48.07 Million USD | 83.015% |
| Adhera Therapeutics, Inc. | -2.11 Million USD | -286.235% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -780.88 Thousand USD | -945.606% |
| Innovation Pharmaceuticals Inc. | -3.16 Million USD | -157.734% |
| Neutra Corp. | -233.46 Thousand USD | -3397.312% |
| Windtree Therapeutics, Inc. | -20.29 Million USD | 59.76% |
| PureTech Health plc | -65.69 Million USD | 87.572% |
| Coeptis Therapeutics, Inc. | -21.26 Million USD | 61.606% |
| IXICO plc | -1.17 Million USD | -593.124% |
| IntelGenx Technologies Corp. | -9.92 Million USD | 17.75% |
| Gelesis Holdings, Inc. | -57.12 Million USD | 85.708% |
| CSL Limited | 2.64 Billion USD | 100.309% |
| Cellectis S.A. | -103.17 Million USD | 92.086% |